Creatinine metabolite, HMH (5-hydroxy-1-methylhydantoin; NZ-419), modulates bradykinin-induced changes in vascular smooth muscle cells

References

• Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801–9
   PubMed Web of Science ®Google Scholar
• Clowes AW, Karnovsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977;265:625–6
   PubMed Web of Science ®Google Scholar
• Clowes AW, Reidy MA, Clowes MA. Kinetics of cellular proliferation after arterial injury. Lab Invest 1983;49:327–33
   PubMed Web of Science ®Google Scholar
• Jackson CL, Schwartz SM. Pharmacology of smooth muscle cell replication. Hypertension 1992;20:713–36
   PubMed Web of Science ®Google Scholar
• Metzler B, Hu Y, Dietrich H, Xu O. Increased expression and activation of stress-activated protein kinases/c-Jun NH(2)-terminal protein kinases in atherosclerotic lesions coincide with p53. Am J Pathol 2000;156:1875–86
   Google Scholar
• Zhu Y, Liao H, Wang N, et al. LDL-activated p38 in endothelial cells is mediated via RAS. ATVB 2001;21:1159–64
   Google Scholar
• Zhao M, Liu Y, Wang X, et al. Activation of the p38 MAP kinase pathway is required for foam cell formation from macrophages exposed to oxidized-LDL. APMIS 2002;110:458–68
   PubMed Web of Science ®Google Scholar
• Lee HS, Kim BC, Hong HK, Kim YS. LDL stimulates collagen synthesis in mesangial cells through induction of PKC and TGF-β. Am J Physiol 1999;277:F369–76
   Google Scholar
• Kamanna VS. Low density lipoprotein and mitogenic signal transduction processes: role in the pathogenesis of renal disease. Histol Pathol 2002;17:497–505
   PubMed Web of Science ®Google Scholar
• Blom IE, Goldschmeding R, Leask A. Gene regulation of CTGF: new targets for anti-fibrotic therapy. Matrix Biol 2002;28:473–82
   Google Scholar
• Daniels A, Bilsen M, Goldschmeding R, et al. Connective tissue growth factor and cardiac fibrosis. Acta Physiol 2009;195:321–38
   PubMed Web of Science ®Google Scholar
• San Martin A, Du P, Dikalova A, et al. Nox1-based NADPH oxidase-derived superoxide is required for VSMC activation by advanced glycation end-products. AJP Heart 2007;42:1697–9
   Google Scholar
• Ohnishi H, Oka T, Kusachi S, et al. Increased expression of CTGF in the infrat zone of experimentally induced myocardial infarction in the rat. J Mol Cell Cardiol 1998;30:2411–22
   PubMed Web of Science ®Google Scholar
• Panek AN, Posch MG, Alenina N, et al. CTGF overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. Plos One 2009;25:e6743
   Google Scholar
• Kulper EJ, Van Zijderveld R, Rosentenberg P, et al. CTGF is necessary for retinal capillary basal lamina thickening in diabetic mice. J Histochem Cytochem 2008;56:785–92
   Google Scholar
• Chintala H, Liu H, Parmar R, et al. CTGF regulates retinal neovascularization through p53 dependent transactivation of the matrix metalloproteinase 2 gene. JBC 2012;287:40570–85
   Google Scholar
• Winkler JL, Kedees MH, Guz Y, Teitelman G. Inhibition of CTGF by small interfering ribonucleic acid prevents increase in extracellular matrix molecules in rodent model of diabetic retinopathy. Mol Vis 2012;18:874–86
   PubMedGoogle Scholar
• Yokoi H, Mukoyama M, Mori K, et al. Overexpression of CTGF in podocytes worsens diabetic nephropathy in mice. Kidney Int 2008;73:446–55
   PubMed Web of Science ®Google Scholar
• Margolius HS. Kallikrein and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension 1995;26:221–9
   PubMed Web of Science ®Google Scholar
• Mombouli JV, Vanhoutte PM. Kinins and endothelial control of vascular smooth muscle. Ann Rev Pharmacol Toxicol 1995;35:679–705
   PubMed Web of Science ®Google Scholar
• Nolly H, Carretero OA, Scicili GA. Kallikrein release by vascular tissue. Am J Physiol 1990;265:H1206–14
   Google Scholar
• Saed G, Carretero OA, MacDonald RJ, Scicli GA. Kallikrein messenger RNA in arteries and veins. Circ Res 1990;67:510–6
   PubMedGoogle Scholar
• Sakakibara T, Hintze TH, Nasjletti A. Determinants of kinin release in isolated rat hindquarters. Am J Physiol 1998;274:R120–5
   Google Scholar
• Ienaga K, Yokozawa T. Creatinine and HMH (5-hydroxy-1-methylhydantoin, NZ-419) as hydroxyl radical scavengers. Drug Discov Ther 2011;5:162–75
   Google Scholar
• Endou H, Ienaga K. Eliminating agent for activated oxygen and free radicals. 1996; US 6,197,806 B1
   Google Scholar
• Ienaga K, Nakamura K, Yamakawa M, et al. The use of 13C-labelling to prove that creatinine is oxidized by mammals into creatol and 5-hydroxy-1-methylhydantoine. J Chem Soc Chem Commun 1991;(7):509–10
   Google Scholar
• Ienaga K, Nakamura K, Ishii A, et al. The stepwise mammalian oxidation of the hydantoin 1-methylimidazolidine-2,4-dione into methylimidazolidinetrione via 5-hydroxy-1-methylimidazolidine-2,4-dione. J Chem Soc Perkin Trans I 1989;(6):1153–6
   Google Scholar
• Ienaga K, Nakamura K, Fukunaga Y, et al. Creatol and chronic renal failure. Kidney Int 1994;47:s22–4
   Google Scholar
• Ienaga K, Nakamura K, Fjisawa T, et al. Urinary excretion of creatol, an in vivo biomarker of hydroxyl radical, in patients with chronic renal failure. Ren Fail 2007;29:279–83
   PubMed Web of Science ®Google Scholar
• Hasegawa G, Nakano K, Ienaga K. Serum accumulation of a creatinine oxidative metabolite (NZ-419: 5-hydroxy-1-methylhydatoin) as an intrinsic antioxidant in diabetic patients with or without chronic kidney disease. Clin Nephrol 2011;76:284–9
   Google Scholar
• National Kidney Foundation: KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1–266
   Google Scholar
• Ienaga K, Mikami H, Yokozawa T. First indications demonstrating the preventive effects of NZ-419, a novel intrinsic antioxidant, on the initiation and/or progression of chronic renal failure in rats. Biol Pharm Bull 2009;32:1204–8
   PubMed Web of Science ®Google Scholar
• Ienaga K, Yokozawa T. Treatment with NZ-419 (5-hydroxy-1-methylimidazoline-2,4-dione), a novel intrinsic antioxidant, against the progression of chronic kidney disease at stages 3 and 4 in rats. Biol Pharm Bull 2010;33:809–15
   Google Scholar
• Ienaga K, Park CH, Yokozawa T. Protective effect of an intrinsic antioxidant, HMH (5-hydroxy-1-methylhydantoin; NZ-419), against cellular damage of kidney tubules. Exp Toxicol Pathol 2013;65:559–66
   Google Scholar
• Velarde V, de la Cerda PM, Duarte C, et al. Role of reactive oxygen species in bradykinin-induced proliferation of vascular smooth muscle cells. Biol Res 2004;37:419–30
   Google Scholar
• Greene EL, Velarde V, Jaffa AA. Role of reactive oxygen species in bradykinin-induced mitogen activated protein kinase and c-fos induction in vascular cells. Hypertension 2000;35:942–7
   PubMedGoogle Scholar
• Majack MA, Cook SC, Bornstein P. Platelet-derived growth factor and heparin-like glycosaminoglycans regulate thrombospondin synthesis and deposition in the matrix of smooth muscle cells. J Cell Biol 1985;101:1059–70
   PubMed Web of Science ®Google Scholar
• US National Institutes of Health: Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85–23, revised 1996)
   Google Scholar
• Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1957;193:265–75
   Google Scholar
• Christopher J, Velarde V, Zhang N, et al. Regulation of B2-kinin receptors by glucose in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2001;280:H1537–46
   Google Scholar
• Aoyagi K, Nagase M, Narita M, et al. Effect of NZ-419, a novel intrinsic anti-oxidant, on hydroxyl radical-mediated synthesis of creatinine metabolites. In Abstracts of the 14th International Congress of Nephrology, Sydney. Nephrology 1997;387
   Google Scholar
• Kichuk MR, Seyedi N, Zhang X, et al. Regulation of nitric oxide production in human coronary microvessels and the contribution of local kinin formation. Circulation 1996;94:44–51
   PubMed Web of Science ®Google Scholar
• Siragy HM, Jaffa AA, Margolius HS. Bradykinin B2 receptors modulates renal prostaglandin E2 and nitric oxide. Hypertension 1997;29:757–62
   Google Scholar
• Grag UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774–7
   PubMed Web of Science ®Google Scholar
• Briner VA, Tsai P, Schrier RW. Bradykinin: potential for vascular constriction in the presence of endothelial injury. Am J Physiol 1993;264:F322–7
   Google Scholar
• Jaffa AA, Usinger WR, McHenry MB, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Group. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab 2008;93:1893–900
   PubMed Web of Science ®Google Scholar
• Tan Y, Wang B, Keum JS, Jaffa AA. Mechanisms through which bradykinin promotes glomerular injury in diabetes. Am J Physiol Renal Physiol 2005;288:F483–92
   Google Scholar
• Sánchez-López E, Rodriguez-Vita J, Cartier C, et al. Inhibitory effect of interleukin-1beta on angiotensin II-induced connective tissue growth factor and type IV collagen production in cultured mesangial cells. Am J Physiol Renal Physiol 2008;294:F149–60
   PubMed Web of Science ®Google Scholar
• Guha M, Xu ZG, Tung D, et al. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 2007;21:3355–68
   PubMed Web of Science ®Google Scholar
• Nguyen TQ, Tarnow L, Jorsal A, et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 2008;31:1177–82
   PubMed Web of Science ®Google Scholar
• Koitabashi N, Arai M, Niwano K, et al. Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur J Heart Fail 2008;10:373–9
   PubMed Web of Science ®Google Scholar
• Douillet CD, Velarde V, Christopher JT, et al. Mechanisms by which bradykinin promotes fibrosis in vascular smooth muscle cells: role of TGF-beta and MAPK. Am J Physiol Heart Circ Physiol 2000;279:H2829–37
   PubMedGoogle Scholar
• Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999;19:2435–44
   PubMed Web of Science ®Google Scholar
• Wetzker R, Bohmer FD. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Mol Cell Biol 2003;4:651–7
   PubMedGoogle Scholar
• Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807–69
   PubMed Web of Science ®Google Scholar
• Lille S, Daum G, Clowes MM, Clowes AW. The regulation of p42/p44 MAPK in the injured rat carotid artery. J Sur Res 1997;70:178–86
   PubMedGoogle Scholar
• Lai K, Wang H, Lee W-S, et al. Mitogen activated protein kinase phosphatase 1 in rat arterial smooth muscle cell proliferation. J Clin Invest 1996;98:1560–7
   Google Scholar
• Touyz RM, Cruzado M, Tabet F, et al. Redox-dependent MAP kinase signaling by Ang II in vascular smooth muscle cells: role of receptor tyrosine kinase transactivation. Can J Physiol Pharmacol 2003;81:159–67
   PubMedGoogle Scholar
• Yang CM, Chien CS, Ma YH, et al. Bradykinin B2 receptor-mediated proliferation via activation of the Ras/Raf/MEK/MAPK pathway in rat vascular smooth muscle cells. J Biomed Sci 2003;10:208–18
   PubMed Web of Science ®Google Scholar
• Ullian ME, Gelasco AK, Fitzgibbon WR, et al. N-Acetylcysteine decreases angiotensin II receptor binding: in vascular smooth muscle cells. J Am Soc Nephrol 2008;16:2346–53
   Google Scholar